A new telehealth platform is offering a more accessible route to GLP-1 medications, which have become a popular treatment for obesity. Effecty, a service focused on weight care, hormone health, and longevity, is providing a compounded semaglutide plan that reduces the initial cost to $45 for the first month.
According to the Centers for Disease Control and Prevention (CDC), over 40% of U.S. adults are obese. While GLP-1 medications have shown efficacy in treating obesity, their high cost, often reaching up to $1,000 per month, presents a significant challenge for many individuals. Effecty's introductory offer, which includes a $100 discount on the first month, aims to mitigate this financial barrier for users signing up for its 12-month plan.
After the initial discounted month, users will pay a consistent flat monthly fee for the program. This pricing structure is designed to remain stable even if a patient's prescription needs adjustment, preventing unexpected cost increases. The service is available nationwide, covering all 50 states, and offers options for installment payments.
Getting started with Effecty involves completing an online questionnaire followed by a telehealth consultation with a state-registered physician. The provider then determines the most suitable course of action, and the medication is shipped directly to the patient's residence. Subscribers also gain access to 24/7 secure messaging with providers and routine check-ins, which can be beneficial for monitoring potential side effects, particularly for new users of GLP-1 medications.